Health knowledge made personal
Join this community!
› Share page:
Search posts:

Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease

Posted Apr 11 2010 5:00pm

Description of Invention:
The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.

Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis.

Researchers from the National Institute on Aging (NIA), NIH, have developed methods for the generation of tBregs, and for using tBregs to produce Tregs, and methods that inactivate or deplete tBregs. These methods have significant therapeutic value in the combat with cancer immune escape and metastasis, and in the control of harmful autoimmune diseases.

  • Production of cellular cancer vaccines
  • Treatments for immune-mediated disorders
  • Treatments for cancer
  • Treatments for chronic viral infections

Development Status:
The technology is currently in the pre-clinical stage of development.

Arya Biragyn (NIA)
Purevdorj B Olkhanud (NIA)

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Immunotherapeutics Unit, National Institute on Aging, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the utilization of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape. Please contact Nicole Darack, Ph.D. at 301-435-3101 or for more information. Click here to view the NCI collaborative opportunity announcement.

Cancer - Therapeutics
Infectious Diseases
Infectious Diseases - Vaccines

For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 2085

Updated: 04/2010

Post a comment
Write a comment:

Related Searches